APA

Harbeck N., Gluz O., Christgen M., Kates R. E., Braun M., Küemmel S., Schumacher C., Potenberg J., Kraemer S., Kleine-Tebbe A., Augustin D., Aktas B., Forstbauer H., Tio J., von Schumann R., Liedtke C., Grischke E., Schumacher J., Wuerstlein R., Kreipe H. H. & Nitz U. A. (20170915). De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chicago

Harbeck Nadia, Gluz Oleg, Christgen Matthias, Kates Ronald Ernest, Braun Michael, Küemmel Sherko, Schumacher Claudia, Potenberg Jochem, Kraemer Stefan, Kleine-Tebbe Anke, Augustin Doris, Aktas Bahriye, Forstbauer Helmut, Tio Joke, von Schumann Raquel, Liedtke Cornelia, Grischke Eva-Maria, Schumacher Johannes, Wuerstlein Rachel, Kreipe Hans Heinrich and Nitz Ulrike Anneliese. 20170915. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Harvard

Harbeck N., Gluz O., Christgen M., Kates R. E., Braun M., Küemmel S., Schumacher C., Potenberg J., Kraemer S., Kleine-Tebbe A., Augustin D., Aktas B., Forstbauer H., Tio J., von Schumann R., Liedtke C., Grischke E., Schumacher J., Wuerstlein R., Kreipe H. H. and Nitz U. A. (20170915). De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MLA

Harbeck Nadia, Gluz Oleg, Christgen Matthias, Kates Ronald Ernest, Braun Michael, Küemmel Sherko, Schumacher Claudia, Potenberg Jochem, Kraemer Stefan, Kleine-Tebbe Anke, Augustin Doris, Aktas Bahriye, Forstbauer Helmut, Tio Joke, von Schumann Raquel, Liedtke Cornelia, Grischke Eva-Maria, Schumacher Johannes, Wuerstlein Rachel, Kreipe Hans Heinrich and Nitz Ulrike Anneliese. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 20170915.